Summit Therapeutics (SMMT) analyst forecast and price target
Analyst forecast
Consensus of 18 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Equal-Weight | $20.00 from $18.00 | Oct 1, 2026 |
| Citigroup | Maintained | Buy | $43.00 from $40.00 | Sep 29, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | — | Sep 23, 2026 |
| Jefferies | Upgraded | Hold → Buy | $25.00 from $15.00 | Sep 9, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | — | Aug 26, 2026 |
| Bernstein | Upgraded | Underperform → Market Perform | $11.90 from $9.80 | Aug 25, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | — | Aug 18, 2026 |
| Leerink Partners | Upgraded | Underperform → Market Perform | $13.00 from $12.00 | Aug 12, 2026 |
| Guggenheim | Maintained | Buy | $38.00 from $40.00 | Jul 24, 2026 |
| Stifel | Maintained | Buy | $38.00 from $45.00 | Jul 24, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | — | Jul 23, 2026 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | May 22, 2026 |
| Bernstein | Initiated Coverage | Underperform | $7.70 | May 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $23.00 from $30.00 | May 4, 2026 |
| Piper Sandler | Maintained | Neutral | $16.00 from $17.00 | May 1, 2026 |
| Stifel | Initiated Coverage | Buy | $45.00 | Apr 8, 2026 |
| Jefferies | Downgraded | Buy → Hold | $15.00 from $42.00 | Mar 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $30.00 from $40.00 | Feb 24, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 | Feb 2, 2026 |
| Citizens | Maintained | Market Outperform | $40.00 | Jan 30, 2026 |
Frequently asked questions
What is the price target for SMMT stock?
The average 12-month analyst price target for Summit Therapeutics (SMMT) is $26.99, with a high estimate of $43.00 and a low of $11.90, across 7 analysts.
Is SMMT a buy, sell, or hold?
Analysts covering Summit Therapeutics currently average a Buy rating: 11 buy, 6 hold and 1 sell, from 18 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for SMMT?
The average price target of $26.99 implies 78.36% upside from the last price of $15.13.
What is the latest analyst rating on SMMT?
On Oct 1, 2026, Barclays maintained Summit Therapeutics at Equal-Weight with a price target of $20.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.